KR900018379A - 암전이 억제인자의 제조방법 - Google Patents

암전이 억제인자의 제조방법 Download PDF

Info

Publication number
KR900018379A
KR900018379A KR1019900007373A KR900007373A KR900018379A KR 900018379 A KR900018379 A KR 900018379A KR 1019900007373 A KR1019900007373 A KR 1019900007373A KR 900007373 A KR900007373 A KR 900007373A KR 900018379 A KR900018379 A KR 900018379A
Authority
KR
South Korea
Prior art keywords
cancer metastasis
cells
warm
blooded animal
producing
Prior art date
Application number
KR1019900007373A
Other languages
English (en)
Other versions
KR0157227B1 (ko
Inventor
마사시 구리모도
류유이찌 모도다
간소오 이와끼
Original Assignee
하야시바라 겐
가부시기가이샤 하야시바라 세이부쓰 가가구겡규우죠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하야시바라 겐, 가부시기가이샤 하야시바라 세이부쓰 가가구겡규우죠 filed Critical 하야시바라 겐
Publication of KR900018379A publication Critical patent/KR900018379A/ko
Application granted granted Critical
Publication of KR0157227B1 publication Critical patent/KR0157227B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

암전이 억제인자의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 암전이 억제인자 산생능을 지닌 배양주화된 인체조혈기관으로 연유하는 세포를 이용하여 암전이 억제인자를 산생시켜 이것을 채취하는 것을 특징으로 하는 암전이억제인자의 제조방법.
  2. 제1항에 있어서, 인체조형기관으로 연유하는 세포가 인체이외의 온혈동물체내에 이식되고, 그 온혈동물을 기르는 과정에서 그 온형동물의 채액을 받으면서 증식하여 얻을 수 있는 세포임을 특징으로 하는 암전이억제인자의 제조방법.
  3. 제2항에 있어서, 인체이외의 온혈동물이 새 또는 포유동물인 것을 특징으로 하는 암전이억제인자의 제조방법.
  4. 제1항에 있어서, 인체조혈기관으로 연유하는 세포가, 인체이외의 온혈동물체내 그렇지 않으며 체외에 부착한 확산챔버내애 이식되고, 그 온혈동물을 기르는 과정에서 그 온혈동물의 체액을 받으면서 증식하여 얻을수 있는 세포임을 특징으로 하는 암전이억제인자의 제조방법.
  5. 제4항에 있어서, 상기 인체이외의 온혈동물이 새 또는 포유동물인 것을 특징으로 하는 암전이억제인자의 제조방법.
  6. 제1항에 있어서, 인체조혈기관으로 연유하는 세포가 T-세포임을 특징으로 하는 암전이억제인자의 제조방법.
  7. 제1항에 있어서, 암전이억제인자의 산생에 있어, 암전이 억제인자산생능을 지닌 배양주화된 인체조혈기로 연유하는 세포에 유도제를 접촉시키는 것을 특징으로 하는 암전이억제인자의 제조방법.
  8. 제7항에 있어서, 암전이억제인자 유도제가 미토겐임을 특징으로 하는 암전이억제인지의 제조방법.
  9. 제1항에 있어서, 암전이억제인자가, 인체대장암으로 연유하는 배양주화된 세포 RPMI 4788(미생물 공업 연구소 조례기생충 제2429호)으로 분석되었을 때 전이억제활성을 나타내고, 인터페론활성, 종양괴상인자활성, 인터로이킨 1활성 및 인터로이킨 2활성을 나타내지 않고, 겔여과법에서 분자량 10,000-45,000의 범위에 있는 물질임을 특징으로 하는 암전이 억제인자의 제조방법.
  10. 제1항에 있어서, 배양주화된 인체조혈기관으로 연유하는 세포가 RAMOS 세포(ATCC CRL 1596) HPB-MLT 세포(FERM BP-2430), MOLT-3세포(ATCC CRL 1552), TALL-1 세포(JCRB 0086) 및 U-937 세포 (ATCC CRL 1593)로 구성된 그룹에서 선택된 것임을 특징으로 하는 암전이억제인자의 제조방법.
  11. 제1항의 방법에 의하여 향상 제조되는 암전이억제인자.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900007373A 1989-05-22 1990-05-22 암 전이 억제인자의 제조방법 KR0157227B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1-128362 1989-05-22
JP1128362A JP2926409B2 (ja) 1989-05-22 1989-05-22 癌転移抑制因子の製造方法
JP89-128362 1989-05-22

Publications (2)

Publication Number Publication Date
KR900018379A true KR900018379A (ko) 1990-12-21
KR0157227B1 KR0157227B1 (ko) 1998-10-15

Family

ID=14982946

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007373A KR0157227B1 (ko) 1989-05-22 1990-05-22 암 전이 억제인자의 제조방법

Country Status (11)

Country Link
US (1) US5126148A (ko)
EP (1) EP0401997B1 (ko)
JP (1) JP2926409B2 (ko)
KR (1) KR0157227B1 (ko)
AT (1) ATE127527T1 (ko)
CA (1) CA2017279A1 (ko)
DE (1) DE69022121T2 (ko)
DK (1) DK0401997T3 (ko)
ES (1) ES2080114T3 (ko)
GR (1) GR3018004T3 (ko)
RU (1) RU2070046C1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3439490B2 (ja) * 1992-09-28 2003-08-25 株式会社林原生物化学研究所 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
JPH1080270A (ja) * 1996-07-19 1998-03-31 Hayashibara Biochem Lab Inc ポリペプチドをプロセッシングする酵素

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785077A (en) * 1986-05-05 1988-11-15 Scripps Clinic And Research Foundation Substantially pure cytotoxicity triggering factor

Also Published As

Publication number Publication date
EP0401997A1 (en) 1990-12-12
DE69022121D1 (de) 1995-10-12
US5126148A (en) 1992-06-30
GR3018004T3 (en) 1996-02-29
KR0157227B1 (ko) 1998-10-15
DK0401997T3 (da) 1995-10-16
RU2070046C1 (ru) 1996-12-10
JP2926409B2 (ja) 1999-07-28
DE69022121T2 (de) 1996-04-04
JPH02308799A (ja) 1990-12-21
CA2017279A1 (en) 1990-11-22
EP0401997B1 (en) 1995-09-06
ES2080114T3 (es) 1996-02-01
ATE127527T1 (de) 1995-09-15

Similar Documents

Publication Publication Date Title
Golde et al. Growth of human bone marrow in liquid culture
Gazdar et al. Establishment of continuous, clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties
KR950700989A (ko) 사람 수지상 세포의 시험관내 생성방법 및 이의 용도(In vitro generation of human dendritic cells and uses thereof)
RU95115822A (ru) Биологические факторы и нейрональные стволовые клетки
OKANO et al. In vitro expansion of the murine pluripotent hemopoietic stem cell population in response to interleukin 3 and interleukin 6: application to bone marrow transplantation
Stevenson et al. Depressed chemotactic responses in vitro of peritoneal macrophages from tumor-bearing mice
GB1450839A (en) Cell growth assemblies for use in cell culture systems
Kedar et al. In vitro induction of cell-mediated immunity to murine leukemia cells. I. Optimization of tissue culture conditions for the generation of cytotoxic lymphocytes
ATE15693T1 (de) Zellkultur-verfahren.
KR900018379A (ko) 암전이 억제인자의 제조방법
EP0094317A3 (en) Production of interleukin and its analogous immune regulating factors
Asaga et al. The enhancement of tumor growth after partial hepatectomy and the effect of sera obtained from hepatectomized rats on tumor cell growth
Keever et al. NK and LAK activities from human marrow progenitors: I. The effects of interleukin-2 and interleukin-1
Schultz et al. Stimulation and inhibition of neoplastic cell growth by tumor promoter-treated macrophages
Kjærgaard et al. Infiltration patterns of short‐and long‐term cultured A‐NK and T‐LAK cells following adoptive immunotherapy
GB1474006A (en) Process for obtaining continuous lines of tumoral cells in vitro
Kitamura et al. Transdifferentiation between Mast Cell Subpopulations: (mast cells/tissue microenvironment/mutant mice/proteoglycans)
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
Yano et al. Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer
ES2082140T3 (es) Procedimiento para obtener proteina celular con actividad anti-hiv.
ES496780A0 (es) Un procedimiento para el cultivo celular in vitro del virus de la hepatitis b.
Quesada et al. Histochemical patterns of human T lymphocyte subpopulations with nonspecific esterase staining
Ripoche et al. Adult hemoglobins are synthesized in yolk sac microenvironment obtained from murine cultured blastocysts
LIAO et al. Changes in HLA‐DR antigen expression on cultured human melanoma cells during theophylline treatment
EP0611263A2 (en) A method to grow "in vitro" til cells

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee